Subcutaneous delivery of sumatriptan in the treatment of migraine and primary headache
Open Access
- 1 January 2012
- journal article
- Published by Taylor & Francis Ltd in Patient Preference and Adherence
- Vol. 6, 27-37
- https://doi.org/10.2147/PPA.S19171
Abstract
Subcutaneous sumatriptan is an effective treatment for pain from acute migraine headache, and can be used in patients with known migraine syndrome and in patients with primary headaches when secondary causes have been excluded. In limited comparative trials, subcutaneous sumatriptan performed in a manner comparable with oral eletriptan and intravenous metoclopramide, was superior to intravenous aspirin and intramuscular trimethobenzamide-diphenhydramine, and was inferior to intravenous prochlorperazine for pain relief. The most common side effects seen with subcutaneous sumatriptan are injection site reactions and triptan sensations. As with all triptans, there is a risk of rare cardiovascular events with subcutaneous sumatriptan and its use should be limited to those without known cerebrovascular disease and limited in those with known cardiovascular risk factors and unknown disease status. In studies of patient preference and tolerability, the subcutaneous formulation has a faster time of onset and high rate of efficacy when compared with the oral formulation, but the oral formulation appears to be better tolerated. It is important to consider the needs of the patient, their past medical history, and what aspects of migraine treatment are most important to the patient when considering treatment of acute migraine or primary headache. Subcutaneous sumatriptan is a good first-line agent for the treatment of pain from acute migraine headaches and primary headaches.Keywords
This publication has 54 references indexed in Scilit:
- Pharmacoepidemiology of triptans in a headache centreCephalalgia, 2010
- Migraine pathogenesis and state of pharmacological treatment optionsBMC Medicine, 2009
- EFNS guideline on the drug treatment of migraine – revised report of an EFNS task forceEuropean Journal of Neurology, 2009
- Pilot Study Evaluating Preference for 3‐mg Versus 6‐mg Subcutaneous SumatriptanHeadache: The Journal of Head and Face Pain, 2005
- Consensus Statement: Cardiovascular Safety Profile of Triptans (5‐HT1B/1D Agonists) in the Acute Treatment of MigraineHeadache: The Journal of Head and Face Pain, 2004
- Tolerability of the TriptansDrug Safety, 2003
- Triptans in MigraineDrugs, 2000
- Chest Symptoms after SumatriptanCephalalgia, 1996
- Long‐term Efficacy of Subcutaneous Sumatriptan Using a Novel Self‐injectorHeadache: The Journal of Head and Face Pain, 1995
- Long-Term Experience with Sumatriptan in the Treatment of MigraineEuropean Neurology, 1993